Home
Clinical Trials
Endostar Combined With Concur...

Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC

Last Updated: 2019-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-25

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01211002

Non-small Cell Lung Cancer

UNKNOWN PHASE4

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

NCT03588494

Quality of Life

UNKNOWN PHASE2/PHASE3

Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer

NCT01218594

Non-small Cell Lung Cancer

UNKNOWN PHASE2

Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma

NCT02513342

Advanced Lung Squamous Carcinoma

UNKNOWN PHASE4

SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer

NCT04274270

Radiotherapy Side Effect

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current study is a observation study in the real world setting. The 500 patients in compliance with Enrollment Criteria will be as the objects of observation. The procedure of study include the period of screening, treating and follow-up. The duration of study is about two and half year. The data entrying will be done by CRC, using the EDC system. CRA will audit the quality of data regularly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unresectable Stage III NSCLC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* untreated pathologically confirmed inoperable stage III NSCLC according to the 8th edition of the American Joint Committee on Cancer staging system;
* at least one measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)1.1;
* 18-75 years of age;
* Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1;
* 10\) FEV1\>1.0 L;
* suitable function of bone marrow, liver, kidney and coagulation

Exclusion Criteria

history of other malignant diseases, uncontrolled hypertension, any contraindications to chemoradiotherapy, pregnancy, breastfeeding or preexisting bleeding diatheses.

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers